The pivotal role of hepatocytes in drug discovery

Weibel, 1969, Correlated morphometric and biochemical studies on the liver cell. I. Morphometric model, stereologic methods, and normal morphometric data for rat liver, J. Cell Biol., 42, 68, 10.1083/jcb.42.1.68 Prentis, 1988, Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964–1985), Br. J. Clin. Pharmacol., 25, 387, 10.1111/j.1365-2125.1988.tb03318.x Riley, 2004, Metabolic screening in vitro: metabolic stability, CYP inhibition and induction, Drug Discov. Today: Technol., 1, 365, 10.1016/j.ddtec.2004.10.008 Van de Waterbeemd, 2003, ADMET in silico modelling: towards prediction paradise?, Nat. Rev. Drug Discov., 2, 192, 10.1038/nrd1032 Kennedy, 1997, Managing the drug discovery/development interface, Drug Discov. Today, 2, 436, 10.1016/S1359-6446(97)01099-4 Reddy, 2005, Validation of a semi-automated human hepatocyte assay for the determination and prediction of intrinsic clearance in discovery, J. Pharm. Biomed. Anal., 37, 319, 10.1016/j.jpba.2004.09.030 Jenkins, 2004, Automated high throughput ADME assays for metabolic stability and cytochrome P450 inhibition profiling of combinatorial libraries, J. Pharm. Biomed. Anal., 34, 989, 10.1016/j.jpba.2003.08.001 Weaver, 2003, Cytochrome P450 inhibition using recombinant proteins and mass spectrometry/multiple reaction monitoring technology in a cassette incubation, Drug Metab. Dispos., 31, 955, 10.1124/dmd.31.7.955 McGinnity, 2005, Prediction of CYP2C9 mediated drug–drug interactions: a comparison using data from recombinant enzymes and human hepatocytes, Drug Metab. Dispos., 33, 1700, 10.1124/dmd.105.005884 Atkinson, 2005, Automated assessment of time-dependent inhibition of human cytochrome P450 enzymes using liquid chromatography-tandem mass spectrometry analysis, Drug Metab. Dispos., 33, 1637, 10.1124/dmd.105.005579 Lim, 2005, Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes, Drug Metab. Dispos., 33, 1211, 10.1124/dmd.104.003475 McGinnity, 2000, Automated definition of the enzymology of drug oxidation by the major human drug metabolizing cytochrome P450s, Drug Metab. Dispos., 28, 1327 Li, 1999, Cryopreserved human hepatocytes: characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug–drug interaction potential, Chem. Biol. Interact., 121, 17, 10.1016/S0009-2797(99)00088-5 Houston, 1997, Prediction of hepatic clearance from microsomes, hepatocytes and liver slices, Drug Metab. Rev., 29, 891, 10.3109/03602539709002237 Grime, 2006, The impact of in vitro binding on in vitro–in vivo extrapolations, projections of metabolic clearance and clinical drug–drug interactions, Curr. Drug Metab., 7, 251, 10.2174/138920006776359266 Obach, 1997, The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data, J. Pharm. Exp. Ther., 283, 46 Clarke, 2001, Utility of metabolic stability screening: comparison of in vitro and in vivo clearance, Xenobiotica, 31, 591, 10.1080/00498250110057350 Ayrton, 2001, Role of transport proteins in drug absorption, distribution and excretion, Xenobiotica, 31, 469, 10.1080/00498250110060969 Griffin, 2004, Comparison of fresh and cryopreserved rat hepatocyte suspensions for the prediction of in vitro intrinsic clearance, Drug Metab. Dispos., 32, 552, 10.1124/dmd.32.5.552 Tucker, 2001, Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-towards a consensus, Clin. Pharmacol. Ther., 70, 103, 10.1067/mcp.2001.116891 Shitara, 2006, Transporters as a determinant of drug clearance and tissue distribution, Eur. J. Pharamaceut. Sci., 27, 425, 10.1016/j.ejps.2005.12.003 Mizuno, 2003, Impact of drug transporter studies on drug discovery and drug development, Pharmacol. Rev., 55, 425, 10.1124/pr.55.3.1 Olinga, 1998, Characterization of the uptake of rocuronium and digoxin in human hepatocytes: carrier specificity and comparison with in vivo data, J. Pharamcol. Exp. Ther., 285, 506 Meier, 1997, Substrate specificity of sinusoidal bile acid and organic anion uptake systems in rat and human liver, Hepatology, 26, 1667, 10.1002/hep.510260641 Riley, 2002, The influence of DMPK as an integrated partner in modern drug discovery, Curr. Drug Metab., 3, 527, 10.2174/1389200023337135 Houston, 1994, Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance, Biochem. Pharmacol., 47, 1469, 10.1016/0006-2952(94)90520-7 Roland, 1973, Clearance concepts in pharmacokinetics, J. Pharmacokinet. Biopharm., 1, 123, 10.1007/BF01059626 Wilkinson, 1975, Commentary: a physiological approach to hepatic drug clearance, Clin. Pharmacol. Ther., 18, 377, 10.1002/cpt1975184377 Pang, 1977, Hepatic clearance of drugs. I. Theoretical considerations of a “well-stirred” model and a “parallel tube” model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocelluar enzyme activity on hepatic drug clearance, J. Pharmacokinet. Biopharm., 5, 625, 10.1007/BF01059688 Roberts, 1985, Hepatic elimination-dispersion model, J. Pharm. Sci., 74, 585, 10.1002/jps.2600740522 Ito, 2004, Comparison of the use of liver models for predicting drug clearance using in vitro kinetic data from hepatic microsomes and isolated hepatocytes, Pharm. Res., 21, 785, 10.1023/B:PHAM.0000026429.12114.7d Iwatsubo, 1996, Prediction of in vivo drug disposition from in vivo data based on physiological pharmacokinetics, Biopharm. Drug Dispos., 17, 273, 10.1002/(SICI)1099-081X(199605)17:4<273::AID-BDD961>3.0.CO;2-R Ito, 1998, Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport, Annu. Rev. Pharmacol. Toxicol., 38, 461, 10.1146/annurev.pharmtox.38.1.461 Niro, 2003, Application of a convective-dispersion model to predict in vivo hepatic clearance from in vitro measurement utilizing cryopreserved human hepatocyes, Curr. Drug Metab., 4, 357, 10.2174/1389200033489334 Rawden, 2005, Microsomal prediction on in vivo clearance and associated interindividual variability of six benzodiazepines in humans, Xenobiotica, 35, 603, 10.1080/00498250500162870 Lin, 1998, Applications and limitations of interspecies scaling and in vitro extrapolation in pharmacokinetics, Drug Metab. Dispos., 26, 1202 Iwatsubo, 1997, Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data, Pharmacol. Ther., 73, 5147, 10.1016/S0163-7258(96)00184-2 Carlile, 1999, Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans, Br. J. Clin. Pharmacol., 47, 625, 10.1046/j.1365-2125.1999.00935.x Riley, 2005, A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes, Drug Metab. Dispos., 33, 1304, 10.1124/dmd.105.004259 Obach, 1996, The importance of non-specific binding in in vitro matrices, its impact on enzyme kinetic studies of drug metabolism reactions, and implications for in vitro–in vivo correlations, Drug Metab. Dispos., 24, 1047 Obach, 1999, Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data. An examination of in vitro half-live approach and nonspecific binding to microsomes, Drug Metab. Dispos., 27, 1350 Ito, 2005, Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches, Pharm. Res., 22, 103, 10.1007/s11095-004-9015-1 Miners, 2006, In vitro–in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises, Biochem. Pharmacol., 71, 1531, 10.1016/j.bcp.2005.12.019 Gillette, 1977, Theoretical aspects of pharmacokinetic drug interactions, Clin. Pharmacol. Ther., 22, 623, 10.1002/cpt1977225part2623 Tang, 2002, Effect of albumin on phenytoin and tolbutamide metabolism in human liver microsomes: an impact more than protein binding, Drug Metab. Dispos., 30, 648, 10.1124/dmd.30.6.648 Baba, 2002, Effects of serum albumin and liver cytocol on CYP2C9- and CYP3A4-mediated drug metabolism, Drug Metab. Pharmacokin., 17, 522, 10.2133/dmpk.17.522 Bachmann, 2003, Prediction of in vivo hepatic clearance from in vitro data using cryopreserved human hepatocytes, Xenobiotia, 33, 475, 10.1080/0049825031000076177 Roland Yeo, 2004, Predicting the clearance of CYP2C9 substrates, Drug Metab. Dispos., 32, 1522, 10.1124/dmd.104.001792 Naritomi, 2001, Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans, Drug Metab. Dispos., 29, 1316 McGinnity, 2004, Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance, Drug Metab. Dispos., 32, 1247, 10.1124/dmd.104.000026 Mistry, 1987, Glucuronidation in vitro and in vivo: comparison of intestinal and hepatic conjugation of morphine, naloxone and buprenorphine, Drug Metab. Dispos., 15, 710 Soars, 2002, In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance, J. Pharmacol. Exp. Ther., 301, 382, 10.1124/jpet.301.1.382 Boase, 2002, In vitro–in vivo correlations for drugs eliminated by glucuronidation: Investigations with the model substrate zidovudine, Br. J. Clin. Pharmacol., 54, 493, 10.1046/j.1365-2125.2002.01669.x Rowland, 2006, In vitro characterization of lamotrigine N2-glucurondation and the lamotrigine-valproic acid interaction, Drug Metab. Dispos., 34, 1055, 10.1124/dmd.106.009340 Uchaipichat, 2006, Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation, Br. J. Clin. Pharmacol., 61, 427, 10.1111/j.1365-2125.2006.02588.x Soars, 2003, The effect of incubation conditions on the enzyme kinetics of UDP-glucuronosyltransferases, Drug Metab. Dispos., 31, 762, 10.1124/dmd.31.6.762 Hagenbuch, 2003, The superfamily of organic anion transporting polypeptides, Biochim. Biophys. Acta, 1609, 1, 10.1016/S0005-2736(02)00633-8 Hagenbuch, 2004, Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties, Pflugers Arch., 447, 653, 10.1007/s00424-003-1168-y Burckhardt, 2000, Structure or renal organic anion and cation transporters, Am. J. Physiol. Renal Physiol., 278, F853, 10.1152/ajprenal.2000.278.6.F853 Hagenbuch, 1996, Effect of antisense oligonucleotides on the expression of hepatocellular bile acid and organic anion uptake systems in Xenopus laevis oocytes, Biochem. J., 316, 901, 10.1042/bj3160901 Kullak-Ublick, 2001, Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver, Gastroenterology, 120, 525, 10.1053/gast.2001.21176 Ismair, 2001, Hepatic uptake of cholecystokinin octapeptide by organic anion-transporting polypeptides OATP4 and OATP8 of rat and human liver, Gastroenterology, 121, 1185, 10.1053/gast.2001.28704 Cui, 2001, Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC1A6, J. Biol. Chem., 276, 9626, 10.1074/jbc.M004968200 Hirano, 2004, Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans, J. Pharmacol. Exp. Ther., 311, 139, 10.1124/jpet.104.068056 Shimizu, 2005, Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans, Drug Metab. Dispos., 33, 1477, 10.1124/dmd.105.004622 Sasaki, 2002, Transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II cell monolayer expressing both human organic anion-transporting polypeptide (OATP2/SLC21A6) and multidrug resistance-associated protein 2 (MRP2/ABCC2), J. Biol. Chem., 277, 6497, 10.1074/jbc.M109081200 Spears, 2005, Directional trans-epithelial transport of organic anions in orcine LLC-PK1 cells that co-express human OATP1B1 (OATP-C) and MRP2, Biochem. Pharmacol., 69, 415, 10.1016/j.bcp.2004.09.026 Cui, 2001, Vectorial transport by double-transfected cells expressing the human uptake transporter SLC21A8 and the apical export pump ABCC2, Mol. Pharmacol., 60, 934, 10.1124/mol.60.5.934 Letschert, 2005, Vectorial transport of the peptide CCK-8 by double-transfected MDCKII cells stably expressing the organic anion transporter OATP1B3 (OATP8) and the export pump ABCC2, J. Pharmacol. Exp. Ther., 313, 549, 10.1124/jpet.104.081224 Kopplow, 2005, Human hepatobiliary transport of organic anions analyzed by quadruple-transfected cells, Mol. Pharmacol., 68, 1031, 10.1124/mol.105.014605 Ghibellini, 2006, Methods to evaluate biliary excretion of drugs in humans: an updated review, Mol. Pharm., 3, 198, 10.1021/mp060011k Sasaki, 2004, Mol. Pharmacol., 66, 450, 10.1124/mol.66.2.330 Kouzuki, 1998, Contribution of sodium taurocholate co-transporting polypeptide to the uptake of its possible substrates into rat hepatocytes, J. Pharmacol. Exp. Ther., 286, 1043 Ishizuka, 1998, Transport of temocaprilat into rat hepatocytes: Role of organic anion transporting polypeptide, J. Pharmacol. Exp. Ther., 287, 37 Shitara, 2003, Function of uptake transporters for taurocholate and estradiol-17β-d-glucuronide in cryopreserved human hepatocytes, Drug Metab. Pharmacokin., 18, 33, 10.2133/dmpk.18.33 Yamashiro, 2006, Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans, Drug Metab. Dispos., 34, 1247, 10.1124/dmd.105.008938 Crespi, 1995, Xenobiotic-metabolizing human cells as tools for pharmacological and toxicological research, Adv. Drug Res., 26, 179, 10.1016/S0065-2490(05)80006-1 Nakajima, 1999, Azelastine N-demethylation by cytochrome P-450 (CYP) 3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs, Drug Metab. Dispos., 27, 1381 Soars, 2002, A comparison of relative abundance, activity factor and inhibitory monoclonal antibody approaches in the characterization of human CYP enzymology, Br. J. Clin. Pharmacol., 55, 175, 10.1046/j.1365-2125.2003.01721.x Hasegawa, 2003, Contribution of organic anion transporters to the renal uptake of anionic compounds and nucleoside derivatives in rat, J. Pharmacol. Exp. Ther., 305, 1087, 10.1124/jpet.102.046847 Shitara, 2002, Comparative inhibitory effects of different compounds on rat oatp1 (sl21a1) and oatp2 (sl21a5)-mediated transport, Pharm. Res., 19, 147, 10.1023/A:1014264614637 Shitara, 2003, Inhibition of transporter-mediated hepatic uptake as a mechanism for drug–drug interaction between cerivastatin and cyclosporin A, J. Pharmacol. Exp. Ther., 204, 610, 10.1124/jpet.102.041921 Shitara, 2004, J. Pharmacol. Exp. Ther., 311, 228, 10.1124/jpet.104.068536 Tirona, 2001, Polymorphisms in OATP-C. Identification of multiple allelic variants associated with altered transport activity among European and African-Americans, J. Biol. Chem., 276, 35669, 10.1074/jbc.M103792200 Michalski, 2002, A naturally occurring mutation in the SLC21A6 gene causing impaired membrane localization of the hepatocyte uptake transporter, J. Biol. Chem., 277, 43058, 10.1074/jbc.M207735200 Nozawa, 2002, Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis, J. Pharmacol. Exp. Ther., 302, 804, 10.1124/jpet.302.2.804 Letschert, 2004, Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8), Pharmacogenetics, 14, 441, 10.1097/01.fpc.0000114744.08559.92 Nishizato, 2003, Polymorphisms of OATP-C (SL21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics, Clin. Pharmacol. Ther., 73, 554, 10.1016/S0009-9236(03)00060-2 Bertz, 1997, Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions, Clin. Pharmacokinet., 32, 210, 10.2165/00003088-199732030-00004 Fuhr, 2000, Induction of drug metabolising enzymes: pharmacokinetic and toxicological consequences in humans, Clin. Pharmacokinet., 38, 493, 10.2165/00003088-200038060-00003 Zhou, 2005, Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs, Clin. Pharmacokinet., 44, 279, 10.2165/00003088-200544030-00005 Cohen, 2000, Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes, Biopharm. Drug Dispos., 21, 353, 10.1002/bdd.249 Oleson, 2004, An evaluation of the P450 inhibition and induction potential of daptomycin in primary human hepatocytes, Chem. Biol. Interact., 150, 137, 10.1016/j.cbi.2004.08.004 Zhao, 2005, Evaluation of time-dependent inactivation of CYP3A in cryopreserved human hepatocytes, Drug Metab. Dispos., 33, 853, 10.1124/dmd.104.002832 Ring, 2005, Effect of tadalafil on cytochrome P450 3A4-mediated clearance: studies in vitro and in vivo, Clin. Pharmacol. Ther., 77, 63, 10.1016/j.clpt.2004.09.006 McGinnity, 2006, Evaluation of time-dependent cytochrome P450 inhibition using cultured human hepatocytes, Drug Metab. Dispos., 34, 1291, 10.1124/dmd.106.009969 Di Marco, 2003, Demethylation of radiolabelled dextromethorphan in rat microsomes and intact hepatocytes, Eur. J. Biochem., 270, 3768, 10.1046/j.1432-1033.2003.03763.x Yao, 2001, Fluvoxamine-theophylline interaction: gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2, Clin. Pharmacol. Ther., 70, 415, 10.1067/mcp.2001.119724 Yao, 2003, Comparison of in vitro and in vivo inhibition potencies of fluvoxamine toward CYP2C19, Drug Metab. Dispos., 31, 565, 10.1124/dmd.31.5.565 Ito, 2005, Impact of parallel pathways of drug elimination and multiple cytochrome P450 involvement on drug–drug interactions: CYP2D6 paradigm, Drug Metab. Dispos., 33, 837, 10.1124/dmd.105.003715 Williams, 2004, Drug–drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios, Drug Metab. Dispos., 32, 1201, 10.1124/dmd.104.000794 Lim, 2005, Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes, Drug Metab. Dispos., 33, 1211, 10.1124/dmd.104.003475 Ito, 2003, Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes, Drug Metab. Dispos., 31, 945, 10.1124/dmd.31.7.945 Mayhew, 2000, An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation, Drug Metab. Dispos., 28, 1031 Bertelsen, 2003, Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine, Drug Metab. Dispos., 31, 289, 10.1124/dmd.31.3.289 Kobayashi, 1995, The effects of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4′-hydroxylase activity in human liver microsomes, Br. J. Clin. Pharmacol., 40, 481, 10.1111/j.1365-2125.1995.tb05793.x Lopez-Garcia, 1994, Thiophene derivatives as new mechanism-based inhibitors of cytochromes P-450: inactivation of yeast-expressing human liver cytochrome P-450 2C9 by tienilic acid, Biochemistry, 33, 166, 10.1021/bi00167a022 Chan, 2000, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4, Life Sci., 67, 3103, 10.1016/S0024-3205(00)00888-2 Kanamitsu, 2000, Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4, Pharm. Res., 17, 419, 10.1023/A:1007572803027 Yamano, 2001, Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data, Drug Metab. Dispos., 29, 443 Dai, 2003, Metabolism-dependent P450 3A4 inactivation with multiple substrates. Abstract from 12th North American ISSX Meeting. Providence, RI, Drug Metab. Rev., 35, 341 McConn, 2004, Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complex-forming drugs, Drug Metab. Dispos., 32, 1083, 10.1124/dmd.32.10.1083 Riley, 2001, The potential pharmacological and toxicological impact of P450 screening, Curr. Opin. Drug Discov. Devel., 4, 45 Lu, 2001, Species comparison in P450 induction: effects of dexamethasone, omeprazole, and rifampin on P450 isoforms 1A and 3A in primary cultured hepatocytes from man, Sprague–Dawley rat, minipig, and beagle dog, Chem. Biol. Interact., 134, 271, 10.1016/S0009-2797(01)00162-4 Riley, 2004, Cellular models for ADMET predictions and evaluation of drug–drug interactions, Curr. Opin. Drug Discov. Dev., 7, 86 LeCluyse, 2000, Expression and regulation of cytochrome P450 enzymes in primary cultures of human hepatocytes, J. Biochem. Mol. Toxicol., 14, 177, 10.1002/(SICI)1099-0461(2000)14:4<177::AID-JBT1>3.0.CO;2-4 Kato, 2005, The quantitative prediction of in vivo enzyme-induction caused by drug exposure from in vitro information on human hepatocytes, Drug Metab. Pharmacokinet., 20, 236, 10.2133/dmpk.20.236 Luo, 2004, CYP3A4 induction by xenobiotics: biochemistry, experimental methods and impact on drug discovery and development, Curr. Drug Metab., 5, 483, 10.2174/1389200043335397 Soars, 2004, An assessment of UDP-glucuronosyltransferase induction using primary human hepatocytes, Drug Metab. Dispos., 32, 140, 10.1124/dmd.32.1.140 Pichard, 1990, A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporine A oxidase) in primary cultures of human hepatocytes and in liver microsomes, Drug Metab. Dispos., 18, 595 Ripp, 2006, Use of immortalized human heptocytes to predict the magnitude of clinical drug-drug interactions caused by CYP3A4 induction, Drug Metab. Dispos., 34, 1742, 10.1124/dmd.106.010132